Amgen pays $650 million for exclusive licence to Cytokinetics' heart failure products
This article was originally published in Scrip
Executive Summary
Amgen will pay Cytokinetics up to $650 million for exercising its option to license worldwide rights to CK-1827452, Cytokinetics' lead investigational small molecule for treating heart failure, which has completed several Phase IIa trials, and any other products arising from the cardiac contractility programme.